FGF21 and metabolic dysfunction-associated steatohepatitis: Another promising FGF21-based drug, Etruxifermin, showed a reduction in hepatic fat and NASH resolution without worsening fibrosis as well as a significant reduction in enhanced liver fibrosis scores.17